How reducing labor time can save on your cell therapy manufacturing costs

Cell & Gene Therapy Insights 2023; 9(8), 899–909

10.18609/cgti.2023.115

Published: 13 September 2023
Innovator Insight
Y Kong, J Kang, J Schoep

In the early clinical development stage of autologous cell therapy manufacture, labor costs often dominate the overall cost of goods sold. However, as manufacturing scales out, the cost of materials—including media and reagents, consumables, and viral vectors—increases as a percentage of the total cost of goods. Economies of scale can be achieved with autologous cell therapy processing—but in order to widen access to these life-saving treatments, it’s crucial that manufacturers utilize solutions that can support reductions in labor costs. In this article, three experts explain how to reduce labor time for certain critical steps of autologous cell therapy manufacturing by using automated and closed systems.